We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Antares Pharma Inc | NASDAQ:ATRS | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 5.595 | 6.16 | 5.60 | 0 | 01:00:00 |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 14A
Proxy Statement Pursuant to Section 14(a) of
the Securities Exchange Act of 1934
Filed by the Registrant ☒
Filed by a Party other than the Registrant ☐
Check the appropriate box:
☐
|
Preliminary Proxy Statement
|
☐
|
Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))
|
☒
|
Definitive Proxy Statement
|
☐
|
Definitive Additional Materials
|
☐
|
Soliciting Material pursuant to § 240.14a-12
|
Antares Pharma, Inc.
|
(Name of Registrant as Specified in its Charter)
|
|
(Name of Person(s) Filing Proxy Statement, if other than the Registrant)
|
Payment of Filing Fee (Check the appropriate box):
☒
|
No fee required.
|
|
|
Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and 0-11.
|
|
|
(1)
|
Title of each class of securities to which transaction applies:
|
|
|
|
|
(2)
|
Aggregate number of securities to which transaction applies:
|
|
|
|
|
(3)
|
Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (set forth the amount on which the filing fee is calculated and state how it
was determined):
|
|
|
|
|
(4)
|
Proposed maximum aggregate value of transaction:
|
|
|
|
|
(5)
|
Total fee paid:
|
|
|
|
☐
|
Fee paid previously with preliminary materials.
|
|
☐
|
Check box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the offsetting fee was paid previously. Identify the
previous filing by registration statement number, or the Form or Schedule and the date of its filing.
|
|
|
(1)
|
Amount Previously Paid:
|
|
|
|
|
(2)
|
Form, Schedule or Registration Statement No.:
|
|
|
|
|
(3)
|
Filing Party:
|
|
|
|
|
(4)
|
Date Filed:
|
|
|
|
|
Sincerely,
|
|
|
|
Robert F. Apple
|
|
President and Chief Executive Officer
|
|
By order of the Board of Directors,
|
|
|
|
Peter J. Graham
|
|
Corporate Secretary
|
|
April 27, 2020
|
|
● |
The date, time and virtual location of the Annual Meeting;
|
|
● |
A brief description of the matters to be voted on at the Meeting;
|
|
● |
A list of the proxy materials available for viewing at www.proxyvote.com;
|
|
● |
The control number you will use to access the site; and
|
|
● |
Instructions on how to access and review the proxy materials online, how to vote your shares over the Internet, and how to get a paper or e-mail copy of the proxy materials, if that is your preference.
|
Page
|
|
1
|
|
3
|
|
6
|
|
6
|
|
6
|
|
6
|
|
6
|
|
7
|
|
8
|
|
9
|
|
9
|
|
9
|
|
9
|
|
9
|
|
9
|
|
11
|
|
12
|
|
14
|
|
16
|
|
18
|
|
18
|
|
18
|
|
19
|
|
19
|
|
19
|
|
27
|
|
27
|
Page
|
|
28
|
|
28
|
|
28
|
|
28
|
|
29
|
|
30
|
|
32
|
|
33
|
|
33
|
|
37
|
|
38
|
|
39
|
|
40
|
|
41
|
|
41
|
|
41
|
|
41
|
|
41
|
|
41
|
|
● |
In person. You may attend the Annual Meeting and deliver your completed proxy card in person (virtually) or complete a ballot (virtually) during the meeting.
|
|
● |
By phone or via the Internet. You may vote by proxy, either by phone or via the Internet, by following the instructions provided in the
Notice, proxy card or voting instruction card.
|
|
● |
By mail. If you request printed copies of the proxy materials by mail, you may vote by proxy by signing and returning the proxy card or voting instruction card.
|
|
● |
Proposal No. 3: the ratification of the appointment of KPMG LLP as our independent registered public accounting firm for our fiscal year ending December 31, 2020.
|
|
● |
Proposal No. 1: the election of Leonard S. Jacob, MD, Ph.D. and Peter S. Greenleaf as Class I directors of the Company’s Board of Directors each for a term of three years and until his successor is duly elected and qualified; and
|
|
● |
Proposal No. 2: the approval of a non-binding, advisory vote for our named executive officer compensation as disclosed in this proxy statement.
|
|
● |
a plurality of the votes cast by stockholders present, in person (virtually) or by proxy, and entitled to vote for the election of directors at the Annual Meeting will be required to elect Leonard S. Jacob, MD, Ph.D. and Peter S.
Greenleaf as Class I directors of the Board of Directors of the Company.
|
|
● |
the affirmative vote of a majority of the votes cast by stockholders present, in person (virtually) or by proxy, and entitled to vote at the Annual Meeting, will be required to:
|
|
○ |
approve, on an advisory basis, our named executive officer compensation as disclosed in our proxy statement; and
|
|
○ |
ratify the appointment of KPMG LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2020.
|
Name
|
Age
|
Class
|
Term Expiry
|
|
Leonard S. Jacob, M.D., Ph.D
|
71
|
I
|
2020 Annual Meeting of Stockholders(1)
|
|
Peter S. Greenleaf
|
50
|
I
|
2020 Annual Meeting of Stockholders(1)
|
|
Anton G. Gueth
|
63
|
II
|
2021 Annual Meeting of Stockholders
|
|
Robert P. Roche, Jr.
|
64
|
II
|
2021 Annual Meeting of Stockholders
|
|
Robert F. Apple
|
54
|
III
|
2022 Annual Meeting of Stockholders
|
|
Thomas J. Garrity
|
71
|
III
|
2022 Annual Meeting of Stockholders
|
|
Karen L. Smith, M.D., Ph.D
|
52
|
III
|
2022 Annual Meeting of Stockholders
|
|
(1) |
If the Class I director nominees are elected at the Annual Meeting, their term will expire in 2023.
|
|
● |
to advise the Board of Directors regarding the membership and operations of the Board of Directors;
|
|
● |
to identify individuals qualified to serve as members of the Board of Directors, to select, subject to ratification by the Board of Directors, the director nominees for the next annual meeting of stockholders, and to recommend to the
Board of Directors individuals to fill vacancies on the Board of Directors;
|
|
● |
to recommend to the Board of Directors the responsibilities of each Committee of the Board of Directors, the structure and operation of each Committee of the Board of Directors, and the director nominees for assignment to each Committee
of the Board of Directors;
|
|
● |
to oversee the Board of Director’s annual evaluation of its performance and the performance of other Committees of the Board of Directors; and
|
|
● |
to develop and recommend to the Board of Directors a set of corporate governance guidelines applicable to the Company and to periodically review the guidelines.
|
|
||||
● Annual Cash Retainer:
|
$
|
45,000
|
||
● Annual Equity Grant:
|
$
|
140,000
|
(1)
|
|
||||
● Audit Committee:
|
$
|
12,000
|
||
● Compensation Committee:
|
$
|
10,000
|
||
● Governance and Nominating Committee:
|
$
|
10,000
|
|
||||
● Audit Committee:
|
$
|
25,000
|
||
● Compensation Committee:
|
$
|
17,000
|
||
● Governance and Nominating Committee:
|
$
|
7,500
|
|
||||
● Annual Cash Retainer:
|
$
|
90,000
|
||
● Annual Equity Grant:
|
$
|
220,000
|
(1)
|
|
(1) |
The annual equity compensation is granted in the form of (i) 50% restricted stock units, which can be deferred until separation from service or a year between 2023 and 2030, as elected by the non-employee director, and (ii) 50%
nonqualified stock options. In June 2019, each existing director, other than the Board Chairman, received a stock option grant to purchase 46,729 shares of our common stock. The Board Chairman received a stock option grant to purchase
73,431 shares of our common stock. In addition, each director, other than the Board Chairman, received 23,973 restricted stock units, and the Board Chairman received 37,671 restricted stock units. The amounts listed above reflect the
combined grant date fair value of such stock option and restricted stock unit grants.
|
Name
|
Fees Earned
or Paid in Cash ($) |
Stock
Awards ($)(2) |
Option
Awards
($)(2)
|
Non-Equity
Incentive Plan Compensation |
Change in
Pension Value and Nonqualified Deferred Compensation Earnings |
All Other
Compensation |
Total ($)
|
Thomas J. Garrity
|
77,747
|
70,000
|
70,000
|
-
|
-
|
-
|
217,747
|
Jacques Gonella, Ph.D.(1)
|
7,500
|
-
|
-
|
-
|
-
|
-
|
7,500
|
Peter S. Greenleaf
|
45,000
|
70,000
|
70,000
|
-
|
-
|
-
|
185,000
|
Anton G. Gueth
|
81,747
|
70,000
|
70,000
|
-
|
-
|
-
|
221,747
|
Leonard S. Jacob, M.D., Ph.D.
|
107,500
|
110,000
|
110,000
|
-
|
-
|
-
|
327,500
|
Robert P. Roche, Jr.
|
57,000
|
70,000
|
70,000
|
-
|
-
|
-
|
197,000
|
Marvin Samson
|
55,000
|
70,000
|
70,000
|
-
|
-
|
-
|
195,000
|
Karen L. Smith, M.D., Ph.D.
|
43,997
|
70,000
|
109,400
|
-
|
-
|
-
|
223,397
|
(1) |
Effective March 1, 2019, Dr. Gonella retired as a member of the Board of Directors. Amounts shown for fees earned were pro-rated based on his period of service in 2019.
|
(2) |
The amounts shown for stock awards and option awards relate to shares granted under the Equity Compensation Plan. These amounts are equal to the aggregate grant date fair value of the awards, computed in accordance with Statement of
Financial Accounting Standards Board Accounting Standards Codification Topic 718 (“FASB ASC 718”). The assumptions used in determining the amounts for option awards are set forth in note 7 to our consolidated financial statements included
in our Annual Report on Form 10-K for the year ended December 31, 2019. The annual option grants vest one year from the date of grant. The initial option award granted to new directors upon joining the board, which was received by Dr. Smith
in 2019, vest in annual installments over three years. At December 31, 2019, these non-employee directors held options to purchase an aggregate of 3,359,902 shares of common stock.
|
|
● |
Reported record annual revenue of $123.9 million for the year ended December 31, 2019, which represented a 95% increase over the prior year.
|
|
● |
Reported annual revenue for our proprietary product, XYOSTED™ (testosterone enanthate), of approximately $20.8 million.
|
|
● |
Reported record annual royalty revenue of $24.2 million, representing a 171% increase over 2018. The significant increase in royalty revenue was primarily driven by royalties received from Teva Pharmaceuticals
from net sales of their generic Epipen®.
|
|
● |
Reported the Company’s first annual operating income of $1.0 million.
|
|
● |
Attained a 73% increase in the Company’s stock price based on the closing price per share on December 31, 2019 compared to December 31, 2018.
|
|
● |
Announced a global agreement with Idorsia Pharmaceuticals Ltd. to jointly develop a novel, drug-device product combining selatogrel, Idorsia’s potent, fast acting and highly selective P2Y12 receptor antagonist
under development with Antares’ subcutaneous Quickshot® auto-injector.
|
|
● |
bookkeeping or other services relating to the accounting records or financial statements,
|
|
● |
financial information systems design and implementation,
|
|
● |
appraisal and valuation services, fairness opinions or contribution-in-kind reports,
|
|
● |
actuarial services,
|
|
● |
internal audit outsourcing services,
|
|
● |
management functions,
|
|
● |
human resource services,
|
|
● |
broker-dealer, investment advisor or investment banking services,
|
|
● |
legal services, and
|
|
● |
expert services unrelated to the audit.
|
Name
|
Age
|
Position
|
Robert F. Apple
|
54
|
President and Chief Executive Officer
|
Fred M. Powell
|
59
|
Executive Vice President, Chief Financial Officer
|
Peter J. Graham
|
53
|
Executive Vice President, General Counsel, Chief Compliance Officer, Human Resources & Corporate Secretary
|
James P. Tursi, M.D.
|
55
|
Executive Vice President, Head of Research and Development, Chief Medical Officer
|
|
● |
Reported record annual revenue of $123.9 million for the year ended December 31, 2019, which represented a 95% increase over the prior year.
|
|
● |
Reported annual revenue for our proprietary product, XYOSTED™ (testosterone enanthate), of approximately $20.8 million.
|
|
● |
Reported record annual royalty revenue of $24.2 million, representing a 171% increase over 2018. The significant increase in royalty revenue was primarily driven by royalties received from Teva Pharmaceuticals
from net sales of their generic Epipen®.
|
|
● |
Reported the Company’s first annual operating income of $1.0 million.
|
|
● |
Attained a 73% increase in the Company’s stock price based on the closing price per share on December 31, 2019 compared to December 31, 2018.
|
|
● |
Announced a global agreement with Idorsia Pharmaceuticals Ltd. to jointly develop a novel, drug-device product combining selatogrel, Idorsia’s potent, fast acting and highly selective P2Y12 receptor antagonist
under development with Antares’ subcutaneous Quickshot® auto-injector.
|
|
● |
compensation should be based on an individual’s level of responsibility, individual performance and Company performance. As employees progress to more senior positions, their compensation should be increasingly linked to Company
performance because they have increased ability to affect our results;
|
|
● |
target compensation should reflect the value of the position in the marketplace. To attract and retain skilled and experienced executives in the highly competitive and dynamic pharmaceutical, medical device and biotech industries, we
must offer a competitive compensation package;
|
|
● |
compensation should be variable, and our programs are designed to pay for performance. We reward outstanding Company performance with above target compensation and provide less than target compensation when Company objectives are not
achieved;
|
|
● |
compensation programs should align the interests of our executive officers with those of our stockholders by evaluating and rewarding our executives’ performance based on key financial and non-financial measurements that we believe are
critical to our success and increasing stockholder value;
|
|
● |
compensation programs should motivate executives to manage our business to meet our short- and long-term objectives, by rewarding them for meeting these objectives; and
|
|
● |
compensation programs should prioritize executive engagement, which is a critical factor to achieving our desired results.
|
|
● |
CEO: 17% base salary and 83% in variable compensation, with the majority in long-term incentives; and
|
|
● |
Other named executive officers (average): 32% base salary and 68% in variable compensation, with the majority in long-term incentives.
|
|
● |
Worked with Pearl Meyer, the Compensation Committee’s independent compensation consultant, to update the Company’s compensation study of our executive compensation as compared to the executive compensation of the companies in our updated
peer group.
|
|
● |
Awarded modest salary increases, as discussed in more detail below under the section entitled “Base Salaries.”
|
|
● |
Awarded annual cash incentive awards, as discussed in more detail below under the section entitled “Annual Incentive Awards.”
|
|
● |
Consistent with our compensation philosophy, made target equity grants positioned between the market 50th and 75th percentiles under the Company’s 2019 long-term incentive program, as discussed in more detail below under the section
entitled “Long-Term Incentives – Equity Compensation.”
|
● Amphastar Pharmaceuticals, Inc.
|
● Intersect ENT, Inc.
|
● ANI Pharmaceuticals, Inc.
|
● Momenta Pharmaceuticals, Inc.
|
● Anika Therapeutics, Inc.
|
● Reata Pharmaceuticals, Inc.
|
● BioDelivery Sciences International, Inc.
|
● Spectrum Pharmaceuticals, Inc.
|
● Cerus Corporation
|
● STAAR Surgical Company
|
● Eagle Pharmaceuticals, Inc.
|
● Vanda Pharmaceuticals Inc.
|
● Heron Therapeutics, Inc.
|
|
● |
we allocate our compensation among base salary and short and long-term incentive compensation target opportunities in such a way as to not encourage excessive risk-taking;
|
|
● |
we apply Company-wide metrics to encourage decision making that is in the best long-term interests of the Company and our stockholders;
|
|
● |
we use a mix of equity award instruments under our long-term incentive program, including both stock options and full value awards; and
|
|
● |
our equity awards vest over multiyear periods and/or vest based on performance.
|
Name
|
Base Salary for 2018 ($)
|
Base Salary after Increase in
February 2019 (effective 1/1/19) ($) |
Base Salary for 2020
(after increase in February 2020) ($) |
Robert F. Apple
|
550,000
|
572,000
|
592,020
|
Fred M. Powell
|
365,525
|
380,000
|
406,600
|
Peter J. Graham
|
382,940
|
395,000
|
408,825
|
James P. Tursi, M.D.
|
425,000
|
431,000
|
439,620
|
Goal
|
Weighting
|
Results
|
Payout
|
2019 GAAP Revenue
|
40%
|
Reported record revenue of $123.9 million for the full year which represented a 95% increase over the prior year
|
60%
|
2019 XYOSTED™ Revenue
|
20%
|
Reported $20.8 million for the full year
|
16.1%
|
New Product Opportunity
|
30%
|
Executed global development agreement with Idorsia and conducted non-clinical studies for ATRS-1901
|
30%
|
Product Development
|
10%
|
Two Board approved new product development concepts – ATRS-1901 and ATRS-1902
|
15%
|
Total
|
100%
|
121.1%
|
Name
|
2019 Target Annual Incentive Award ($)
|
2019 Actual Annual Incentive
Payout ($) |
Percentage of 2019 Target Annual Incentive Award Actually Paid (%)
|
Robert F. Apple
|
371,800
|
427,124
|
115%
|
Fred M. Powell
|
171,000
|
196,445
|
115%
|
Peter J. Graham
|
177,750
|
204,199
|
115%
|
James P. Tursi
|
193,950
|
222,810
|
115%
|
Name
|
2019 Target Long-term Incentive Award ($)
|
Target Value in PSUs(2)
(33%) ($)
|
Target Value in RSUs(2)
(33%) ($)
|
Target Value in Stock Options(2)
(34%) ($)
|
Robert F. Apple
|
2,500,000
|
825,000
|
825,000
|
850,000
|
Fred M. Powell
|
800,000
|
264,000
|
264,000
|
272,000
|
Peter J. Graham
|
750,000
|
247,500
|
247,500
|
255,000
|
James P. Tursi(1)
|
400,000
|
132,000
|
132,000
|
136,000
|
|
● |
2021 fiscal year end net revenue (30%)
|
|
● |
FDA approval of at least three (3) new products (proprietary or partnered) and the acquisition or in-license of one early stage new development product during the three-year measurement period (40%)
|
|
● |
Three-year total stockholder return (“TSR”) relative to the NASDAQ Biotechnology Index (30%)
|
|
• |
50% payout if relative TSR is equal to or greater than 50th, but less than the 65th percentile of the index
|
|
• |
100% payout if relative TSR is equal to or greater than 65th, but less than the 80th percentile of the index
|
|
• |
150% payout if relative TSR is equal to or greater than the 80th percentile of the index
|
Named Executive Officer
|
Minimum Number of
Actual Shares That May Be Earned |
Target Number of
Shares that May Be Earned |
Maximum Number of
Actual Shares That May Be Earned |
Robert F. Apple
|
0
|
275,600
|
413,400
|
Fred M. Powell
|
0
|
88,193
|
132,290
|
Peter J. Graham
|
0
|
82,680
|
124,020
|
James P. Tursi(1)
|
0
|
44,097
|
66,146
|
Named Executive
Officer
|
Number of Restricted
Stock Units
|
Number of Stock Options
|
Robert F. Apple
|
282,534
|
567,423
|
Fred M. Powell
|
90,411
|
181,575
|
Peter J. Graham
|
84,760
|
170,227
|
James P. Tursi(1)
|
45,205
|
90,788
|
Name and Principal
|
Year
|
Salary ($)
|
Bonus
($)(1) |
Stock
Awards($)(2) |
Option
Awards($)(3) |
Non-Equity
Incentive Plan Compensation ($)(4) |
All Other
Compensation ($)(5) |
Total ($)
|
Robert F. Apple
|
2019
|
572,000
|
-
|
1,651,248(7)
|
850,300
|
427,124
|
14,283
|
3,514,955
|
Chief Executive Officer
|
2018
|
550,000
|
-
|
1,708,070(12)
|
849,766
|
331,298
|
13,746
|
3,452,880
|
2017
|
527,850
|
11,613
|
1,954,304(6)
|
993,999
|
196,138
|
13,496
|
3,697,400
|
|
Fred M. Powell(8)
|
2019
|
380,000
|
-
|
528,403(14)
|
272,096
|
196,445
|
14,283
|
1,391,227
|
Executive Vice President
|
2018
|
365,525
|
-
|
512,425(13)
|
254,930
|
180,145
|
13,746
|
1,326,771
|
Chief Financial Officer
|
2017
|
345,000
|
6,210
|
586,288(9)
|
298,200
|
104,887
|
13,496
|
1,354,081
|
Peter J. Graham
|
2019
|
395,000
|
-
|
495,374(10)
|
255,090
|
204,199
|
14,283
|
1,363,946
|
Executive Vice President,
|
2018
|
382,940
|
-
|
512,425(13)
|
254,930
|
188,728
|
13,746
|
1,352,769
|
General Counsel, Chief Compliance Officer, Human Resources and Corporate Secretary
|
2017
|
369,990
|
6,660
|
586,288(9)
|
298,200
|
112,484
|
10,746
|
1,384,368
|
James P. Tursi (11)
|
2019
|
431,000
|
-
|
264,201(15)
|
136,049
|
222,810
|
13,783
|
1,067,843
|
Executive Vice President
|
2018
|
172,452
|
-
|
-
|
229,000
|
88,469
|
499
|
490,420
|
Chief Medical Officer
|
|
(1) |
The 2017 amounts represent a discretionary bonus awarded for significant efforts to respond expediently and efficiently to the complete response letter received from the FDA in October 2017 in connection with XYOSTED®.
|
|
(2) |
This column shows the aggregate grant date fair value, computed in accordance with FASB ASC 718 for all restricted stock unit and performance-based restricted stock unit awards granted under the Plan in Fiscal 2019, 2018 and 2017. The
grant date fair values of the performance-based restricted stock unit awards were determined based on the probable (i.e., the target) number of shares that could be awarded to each named executive officer. The assumptions used in
determining the amounts in this column are set forth in note 7 to our consolidated financial statements included in our Annual Report on Form 10-K for the year ended December 31, 2019. The following table shows the aggregate grant date fair
value of the performance-based restricted stock unit awards granted in 2019 assuming that the highest level of performance is achieved:
|
Name
|
Number of Shares
Assuming Maximum Performance (#) |
Grant Date
Fair Value Assuming Maximum Performance ($) |
Robert F. Apple
|
413,400
|
1,239,373
|
Peter J. Graham
|
124,020
|
371,812
|
Fred M. Powell
|
132,290
|
396,604
|
James P. Tursi
|
66,146
|
198,304
|
|
(3) |
The amounts shown for option awards relate to option awards granted under the Plan. These amounts are equal to the aggregate grant date fair value of the awards, computed in accordance with Statement of FASB ASC 718. The assumptions used
in determining the amounts in this column are set forth in note 7 to our consolidated financial statements included in our Annual Report on Form 10-K for the year ended December 31, 2019. For information regarding the number of shares
subject to 2019 awards, other features of those awards, and the grant date fair value of the awards, see the Grants of Plan-Based Awards Table. In connection with Dr. Tursi’s resignation effective April 17, 2020, the option award granted in
2019 and a portion of the option award granted in 2018 were forfeited.
|
|
(4) |
The amounts shown represent performance based incentive compensation paid in cash.
|
|
(5) |
The amounts in this column include Company matching contributions under the Company’s 401(k) plan, term life and disability insurance premiums.
|
Name
|
401(k) Plan
Company Match ($) |
Life
Insurance Premiums ($) |
Disability
Insurance Premiums ($) |
Robert F. Apple
|
12,500
|
768
|
1,015
|
Fred M. Powell
|
12,500
|
768
|
1,015
|
Peter J. Graham
|
12,500
|
768
|
1,015
|
James P. Tursi
|
12,000
|
768
|
1,015
|
Name
|
401(k) Plan
Company Match ($) |
Life
Insurance Premiums ($) |
Disability
Insurance Premiums ($) |
Robert F. Apple
|
12,250
|
768
|
728
|
Fred M. Powell
|
12,250
|
768
|
728
|
Peter J. Graham
|
12,250
|
768
|
728
|
James P. Tursi
|
-
|
256
|
243
|
Name
|
401(k) Plan
Company Match ($) |
Life
Insurance Premiums ($) |
Disability
Insurance Premiums ($) |
Robert F. Apple
|
12,000
|
768
|
728
|
Fred M. Powell
|
12,000
|
768
|
728
|
Peter J. Graham
|
9,250
|
768
|
728
|
|
(6) |
Represents the aggregate grant date fair value of $1,054,918 for performance-based restricted stock unit awards and $899,386 for restricted stock unit awards.
|
|
(7) |
Represents the aggregate grant date fair value of $826,249 for performance-based restricted stock unit awards and $824,999 for restricted stock unit awards.
|
|
(8) |
Mr. Powell joined our Company as our Senior Vice President, Chief Financial Officer on October 31, 2016. He now serves as our Executive Vice President, Chief Financial Officer.
|
|
(9) |
Represents the aggregate grant date fair value of $316,473 for performance-based restricted stock unit awards and $269,814 for restricted stock unit awards.
|
|
(10) |
Represents the aggregate grant date fair value of $247,875 for performance-based restricted stock unit awards and $247,499 for restricted stock unit awards.
|
|
(11) |
Dr. Tursi joined the Company as Executive Vice President, Chief Medical Officer on August 6, 2018 and resigned effective April 17, 2020.
|
|
(12) |
Represents the aggregate grant date fair value of $883,069 for performance-based restricted stock unit awards and $825,001 for restricted stock unit awards.
|
|
(13) |
Represents the aggregate grant date fair value of $264,924 for performance-based restricted stock unit awards and $247,501 for restricted stock unit awards.
|
|
(14) |
Represents the aggregate grant date fair value of $264,403 for performance-based restricted stock unit awards and $264,000 for restricted stock unit awards.
|
|
(15) |
Represents the aggregate grant date fair value of $132,203 for performance-based restricted stock unit awards and $131,999 for restricted stock unit awards, and all such awards were forfeited upon Dr. Tursi’s resignation effective April
17, 2020.
|
Estimated
Future Payouts Under Non-Equity Incentive Plan Awards |
Estimated Future Payouts
Under Equity Incentive Plan Awards |
All
Other Stock Awards: Number of Shares of Stock or Units (#) (3) |
All Other
Option Awards: Number of Securities Underlying Options (#) (4) |
Exercise
or Base Price of Option Awards ($/Sh) |
Grant Date
Fair Value of Stock and Option Awards $(5) |
||||
Name
|
Grant
Date |
Target
($)(1) |
Threshold
(#)(2) |
Target
(#)(2) |
Maximum
(#)(2)
|
||||
Robert F. Apple
|
6/13/19
|
-
|
-
|
-
|
-
|
-
|
567,423
|
2.92
|
850,300
|
|
6/13/19
|
-
|
-
|
-
|
-
|
282,534
|
-
|
-
|
824,999
|
|
6/13/19
|
-
|
137,800
|
275,600
|
413,400
|
-
|
-
|
-
|
826,249
|
|
-
|
371,800
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Fred M. Powell
|
6/13/19
|
-
|
-
|
-
|
-
|
-
|
181,575
|
2.92
|
272,096
|
6/13/19
|
-
|
-
|
-
|
-
|
90,411
|
-
|
-
|
264,000
|
|
6/13/19
|
-
|
44,097
|
88,193
|
132,290
|
-
|
-
|
-
|
264,403
|
|
|
-
|
171,000
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
|
|||||||||
Peter J. Graham
|
6/13/19
|
-
|
-
|
-
|
-
|
-
|
170,227
|
2.92
|
255,090
|
6/13/19
|
-
|
-
|
-
|
-
|
84,760
|
-
|
-
|
247,499
|
|
6/13/19
|
-
|
41,340
|
82,680
|
124,020
|
-
|
-
|
-
|
247,875
|
|
-
|
177,750
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
|
James P. Tursi(6)
|
6/13/19
|
-
|
-
|
-
|
-
|
-
|
90,788
|
2.92
|
136,049
|
6/13/19
|
-
|
-
|
-
|
-
|
45,205
|
-
|
-
|
131,999
|
|
6/13/19
|
-
|
22,049
|
44,097
|
66,146
|
-
|
-
|
-
|
132,203
|
|
-
|
193,950
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
|
(1) |
The amounts reflected are the 2019 annual incentive awards for each named executive officer assuming target level performance.
|
|
(2) |
Represent performance stock unit awards made to the executive officers which will be earned and vested and converted into actual shares of the Company’s common stock based on the Company’s attainment of certain performance goals measured
over the three-year period beginning January 1, 2019 and ending December 31, 2021, respectively, and the executive officer’s continued employment with the Company through that period. The actual number of shares of the Company’s common
stock into which the performance stock units may convert will be calculated by multiplying the number of performance stock units by a performance percentage ranging from 0% to 150% based on the attained level of Company performance as
measured in terms of the following three performance goals: multiple pipeline product approvals within the three year period ended December 31, 2021 (weighted at 40%), one related to 2021 fiscal year end net revenue (weighted at 30%) and
one related to the Company’s three-year total stockholder return as compared to the companies in the NASDAQ Biotechnology Index over the same period (weighted at 30%). Each performance criterion has levels of achievement designated as
threshold, target and maximum with 50% of the performance stock units earned if the threshold level is achieved; 100% of the performance stock units earned if the target level is achieved and 150% of the performance stock units earned if
the maximum level is achieved. The actual number of performance stock units earned and vested will be based on the actual performance level achieved. In the event that the actual performance level achieved does not meet threshold
performance (i.e., less than 50%) for an applicable performance measure, then no performance stock units will be earned and vested for that performance measure. Threshold level performance may be achieved for one performance measure and not
another based on the Company’s actual performance during the three-year performance period.
|
|
(3) |
The stock unit awards were granted under the Plan. The stock unit awards vest over three years, vesting as to 33.33% of the units annually following the date of grant.
|
|
(4) |
The option awards were granted under the Plan. Option awards generally vest over three years, becoming exercisable as to 33.33% of the underlying shares annually following the date of grant. Option awards generally become fully
exercisable in the event of the grantee’s death, or termination of employment in connection with a change of control.
|
|
(5) |
The grant date fair value is computed in accordance with Financial Accounting Standard Board Accounting Standard Codification Topic 718.
|
|
(6) |
As a result of Dr. Tursi’s resignation effective April 17, 2020, all awards shown in this table were forfeited.
|
|
|
Option Awards
|
Stock Awards
|
||||||
Name
|
Grant
Date*
|
Number of
Securities Underlying Unexercised Options Exercisable (1) |
Number of
Securities Underlying Unexercised Options Unexercisable (1) |
Option
Exercise Price ($) |
Option
Expiration Date |
Number
of Shares or Units of Stock That Have Not Vested (#) |
Market
Value of Shares or Units of Stock That Have Not Vested ($)(2) |
Equity
Incentive Plan Awards: Number of Unearned Shares, Units or Other Rights That Have Not Vested (#) |
Equity
Incentive Plan Awards: Market or Payout Value of Unearned Shares, Units or Other Rights That Have Not Vested ($)(2) |
Robert F. Apple
|
7/6/12
|
21,658
|
-
|
4.26
|
7/5/22
|
-
|
-
|
-
|
-
|
5/29/14
|
56,300
|
-
|
3.09
|
5/28/24
|
-
|
-
|
-
|
-
|
|
3/10/15
|
95,500
|
-
|
2.62
|
3/9/25
|
-
|
-
|
-
|
-
|
|
5/28/15
|
288,786
|
-
|
2.18
|
5/28/25
|
-
|
-
|
-
|
-
|
|
3/10/16
|
250,000
|
-
|
0.88
|
3/10/26
|
-
|
-
|
-
|
-
|
|
6/2/16
|
773,700
|
-
|
1.12
|
6/2/26
|
-
|
-
|
-
|
-
|
|
6/7/17
|
604,790
|
120,961
|
2.66
|
6/7/27
|
112,705
|
529,714
|
338,115
|
1,589,141
|
|
6/8/18
|
295,746
|
295,764
|
2.70
|
6/8/28
|
203,702
|
957,399
|
305,556
|
1,436,112
|
|
6/13/19
|
-
|
567,423
|
2.92
|
6/13/29
|
282,534
|
1,327,910
|
275,600
|
1,295,320
|
|
Fred M. Powell
|
10/31/16
|
150,000
|
-
|
1.76
|
10/31/26
|
-
|
-
|
-
|
-
|
6/7/17
|
181,440
|
36,285
|
2.66
|
6/7/27
|
33,812
|
158,916
|
101,434
|
476,740
|
|
6/8/18
|
88,722
|
88,731
|
2.70
|
6/8/28
|
61,111
|
287,222
|
91,668
|
430,839
|
|
6/13/19
|
-
|
181,575
|
2.92
|
6/13/29
|
90,411
|
424,932
|
88,193
|
414,507
|
|
Peter J. Graham
|
7/14/15
|
125,000
|
-
|
2.29
|
7/14/25
|
-
|
-
|
-
|
-
|
6/2/16
|
257,900
|
-
|
1.12
|
6/2/26
|
-
|
-
|
-
|
-
|
|
6/7/17
|
181,440
|
36,285
|
2.66
|
6/7/27
|
33,812
|
158,916
|
101,434
|
476,740
|
|
6/8/18
|
88,722
|
88,731
|
2.70
|
6/8/28
|
61,111
|
287,222
|
91,668
|
430,839
|
|
6/13/19
|
-
|
170,227
|
2.92
|
6/13/29
|
84,760
|
398,372
|
82,680
|
388,596
|
|
James P. Tursi
|
8/6/2018
|
62,500
|
87,500
|
2.89
|
8/6/28
|
-
|
-
|
-
|
-
|
6/13/19
|
-
|
90,788
|
2.92
|
6/13/29
|
45,205
|
212,464
|
44,097
|
207,256
|
|
* |
For better understanding of this table, we have included an additional column showing the grant date of the stock options and stock awards.
|
|
(1) |
Option awards generally vest in annual or quarterly installments over a three-year period from the date of grant.
|
|
(2) |
The dollar values are based on the closing price of our Common Stock on December 31, 2019, which was $4.70.
|
Option Awards
|
Stock Awards
|
|||
Name
|
Number of
Shares Acquired on Exercise |
Value Realized
on Exercise ($) |
Number of
Shares Acquired on Vesting (1) |
Value Realized on
Vesting ($)(2) |
Robert F. Apple
|
466,524(3)
|
946,638
|
589,813
|
1,754,094
|
Fred M. Powell
|
-
|
-
|
64,367
|
180,871
|
Peter J. Graham
|
-
|
-
|
189,451
|
564,597
|
|
(1) |
Represents stock units that vested based on their normal vesting schedule and the vesting of performance stock unit awards based on achievement of specific performance goals and completing the requisite service period. A portion of the
shares acquired on vesting were used to cover withholding taxes on the value of the shares that vested, reducing the number of shares actually issued to 371,848 for Mr. Apple, 46,074 for Mr. Powell and 117,045 shares for Mr. Graham.
|
|
(2) |
Represents the value of the shares of stock that vested in 2019 using the market value of the shares on the applicable vesting date.
|
|
(3) |
A portion of the option awards were net settled such that 43,445 shares were withheld upon exercise to satisfy the payment of exercise price and tax liability, reducing the total number of shares actually issued to 423,079.
|
|
● |
one and one-half times the sum of (i) his then-current annual base salary, plus (ii) his target annual bonus for the year in which the termination of employment occurs paid in monthly installments over the 18-month period following
termination of employment, or in the case of Mr. Apple, two times the sum of (A) his then-current annual base salary, plus (B) his target annual bonus for the year in which the termination of employment occurs paid in monthly installments
over the 24-month period following termination of employment;
|
|
● |
a pro-rated annual bonus payment for the year of termination based on actual performance and the number of days that the named executive officer was employed by the Company in the year of his termination;
|
|
● |
reimbursement for the cost of continued health and dental benefits through COBRA, subject to the same cost-sharing as if he were an employee, for the shorter of 18 months, or until the date the executive obtains coverage from a new
employer; and
|
|
● |
all outstanding equity grants held by the executive immediately prior to his termination date which vest over time based upon the officer’s continued service will accelerate, become fully vested and/or exercisable, as the case may be, as
of the termination date and all outstanding equity grants held by the executive immediately prior to his termination date which vest based upon attainment of performance criteria will remain subject to the terms and conditions of the
agreement evidencing such performance based award.
|
|
● |
the sum of (i) his then-current annual base salary, plus (ii) his target annual bonus for the year in which the termination of employment occurs, paid in monthly installments over the 12-month period following termination of employment,
or in the case of Mr. Apple, one and one-quarter times the sum of (A) his then-current annual base salary, plus (B) his target annual bonus for the year in which the termination of employment occurs, paid in monthly installments over the
15-month period following termination of employment;
|
|
● |
a pro-rated annual bonus payment for the year of termination based on actual performance and the number of days the executive was employed by the Company in the year of his termination;
|
|
● |
reimbursement for the cost of continued health and dental benefits through COBRA, subject to the same cost-sharing as if the executive were an employee, for the shorter of 12 months for Messrs. Powell, Graham and Dr. Tursi and 15 months
for Mr. Apple, or until the date he obtains coverage from a new employer; and
|
|
● |
with respect to all outstanding equity grants held by the executive immediately prior to his termination date which vest over time based upon the named executive officer’s continued service, the portion that would have become vested
during the 12 month period (or 15-month period for Mr. Apple) following the named executive officer’s termination date had he remained
|
|
Severance Payment
($)(1) |
Pro-rated
Bonus ($)(2) |
Accelerated
Equity ($)(3) |
All Other
Compensation ($)(4) |
Total
($) |
Termination without cause
|
1,179,750
|
427,124
|
2,527,405
|
35,463
|
4,169,742
|
Termination for good reason
|
1,179,750
|
427,124
|
2,527,405
|
35,463
|
4,169,742
|
Non-renewal of agreement
|
1,179,750
|
427,124
|
2,527,405
|
35,463
|
4,169,742
|
Change of control(5)
|
1,887,600
|
427,124
|
8,983,884
|
42,555
|
11,341,163
|
|
(1) |
Payable in regular payroll installments over 15 months if the termination occurs before or after the Change in Control Protection Period, or over 24 months if the termination occurs during the Change in Control Protection Period.
|
|
(2) |
Represents the pro-rated annual bonus payment for 2019, based on actual performance and the number of days that Mr. Apple was employed by the Company in 2019, payable in a lump sum.
|
|
(3) |
Includes the value of the unvested stock options, time-based restricted stock unit grants and, with respect to a change of control, performance-based restricted stock unit grants held by Mr. Apple as of December 31, 2019. If the
termination occurs before or after the Change in Control Protection Period, the portion of the outstanding stock options and time-based restricted stock units that would have become vested during the 15-month period following his
termination date had he remained employed during such 15-month period will accelerate, become fully vested and/or exercisable, as the case may be, as of the employment termination date. If the termination occurs during the Change in Control
Protection Period, all of the outstanding time-based equity grants will accelerate upon termination of employment. The performance-based restricted stock unit grants will vest at target on a change of control.
|
|
(4) |
All Other Compensation consists of the continuation of health and dental insurance benefits for either 15 months, or, if the termination occurs upon or within 12 months following a change of control, 18 months.
|
|
(5) |
These amounts assume that Mr. Apple’s employment was terminated without cause or for good reason on the date of a change of control.
|
|
Severance Payment
($)(1) |
Pro-rated
Bonus ($)(2) |
Accelerated Equity
($)(3) |
All Other
Compensation ($)(4) |
Total
($) |
Termination without cause
|
551,000
|
196,445
|
744,232
|
28,370
|
1,520,047
|
Termination for good reason
|
551,000
|
196,445
|
744,232
|
28,370
|
1,520,047
|
Non-renewal of agreement
|
551,000
|
196,445
|
744,232
|
28,370
|
1,520,047
|
Change of control(5)
|
826,500
|
196,445
|
2,767,838
|
42,555
|
3,833,338
|
|
(1) |
Payable in regular payroll installments over 12 months if the termination occurs before or after the Change in Control Protection Period or over 18 months if the termination occurs during the Change in Control Protection Period.
|
|
(2) |
Represents the pro-rated annual bonus payment for 2019, based on actual performance and the number of days that Mr. Powell was employed by the Company in 2019, payable in a lump sum.
|
|
(3) |
Includes the value of the unvested stock options, time-based restricted stock unit grants and, with respect to a change of control, performance-based restricted stock unit grants held by Mr. Powell as of December 31, 2019. If the
termination occurs before or after the Change in Control Protection Period, the portion of the outstanding stock options and time-based restricted stock units that would have become vested and exercisable during the 12-month period
following his termination date had he remained employed during such 12-month period will accelerate, become fully vested and/or exercisable, as the case may be, as of the employment termination date. If the termination occurs during the
Change in Control Protection Period, all of the outstanding time-based equity grants will accelerate and become exercisable upon termination of employment. The performance-based restricted stock unit grants will vest at target upon a change
of control.
|
|
(4) |
All Other Compensation consists of the continuation of health and dental insurance benefits for either 12 months, or, if the termination occurs during the Change of Control Protection Period, 18 months.
|
|
(5) |
These amounts assume that Mr. Powell’s employment was terminated without cause or for good reason on the date of a change of control.
|
|
Severance Payment
($)(1) |
Pro-rated
Bonus ($)(2) |
Accelerated Equity
($)(3) |
All Other
Compensation ($)(4) |
Total
($) |
Termination without cause
|
572,750
|
204,199
|
728,645
|
28,370
|
1,533,965
|
Termination for good reason
|
572,750
|
204,199
|
728,645
|
28,370
|
1,533,965
|
Non-renewal of agreement
|
572,750
|
204,199
|
728,645
|
28,370
|
1,533,965
|
Change of control(5)
|
859,125
|
204,199
|
2,695,167
|
42,555
|
3,801,047
|
|
(1) |
Payable in regular payroll installments over 12 months if the termination occurs before or after the Change in Control Protection Period or over 18 months if the termination occurs during the Change in Control Protection Period.
|
|
(2) |
Represents the pro-rated annual bonus payment for 2019, based on actual performance and the number of days that Mr. Graham was employed by the Company in 2019, payable in a lump sum.
|
|
(3) |
Includes the value of the unvested stock options, time-based restricted stock unit grants and, with respect to a change of control, performance-based restricted stock unit grants held by Mr. Graham as of December 31, 2019. If the
termination occurs before or after the Change in Control Protection Period, the portion of the outstanding stock options and time-based restricted stock units that would have become vested and exercisable during the 12-month period
following his termination date had he remained employed during such 12-month period will accelerate, become fully vested and/or exercisable, as the case may be, as of the employment termination date. If the termination occurs during the
Change in Control Protection Period, all of the outstanding time-based equity grants will accelerate and become exercisable upon termination of employment. The performance-based restricted stock unit grants will vest at target upon a change
of control.
|
|
(4) |
All Other Compensation consists of the continuation of health and dental insurance benefits for either 12 months, or, if the termination occurs during the Change of Control Protection Period, 18 months.
|
|
(5) |
These amounts assume that Mr. Graham’s employment was terminated without cause or for good reason on the date of a change of control.
|
|
Severance Payment
($)(1) |
Pro-rated
Bonus ($)(2) |
Accelerated Equity
($)(3) |
All Other
Compensation ($)(4) |
Total
($) |
Termination without cause
|
624,950
|
222,810
|
215,189
|
28,370
|
1,091,318
|
Termination for good reason
|
624,950
|
222,810
|
215,189
|
28,370
|
1,091,318
|
Non-renewal of agreement
|
624,950
|
222,810
|
215,189
|
28,370
|
1,091,318
|
Change of control(5)
|
937,425
|
222,810
|
739,697
|
42,555
|
1,942,487
|
|
(1) |
Payable in regular payroll installments over 15 months if the termination occurs before or after the Change in Control Protection Period, or over 24 months if the termination occurs during the Change in Control Protection Period.
|
|
(2) |
Represents the pro-rated annual bonus payment for 2019, based on actual performance and the number of days that Dr. Tursi was employed by the Company in 2019, payable in a lump sum.
|
|
(3) |
Includes the value of the unvested stock options, time-based restricted stock unit grants and, with respect to a change of control, performance-based restricted stock unit grants held by Dr. Tursi as of December 31, 2019. If the
termination occurs before or after the Change in Control Protection Period, the portion of the outstanding stock options and time-based restricted stock units that would have become vested during the 15-month period following his
termination date had he remained employed during such 15-month period will accelerate, become fully vested and/or exercisable, as the case may be, as of the employment termination date. If the termination occurs during the Change in Control
Protection Period, all of the outstanding time-based equity grants will accelerate upon termination of employment. The performance-based restricted stock unit grants will vest at target on a change of control.
|
|
(4) |
All Other Compensation consists of the continuation of health and dental insurance benefits for either 12 months, or, if the termination occurs during the Change of Control Protection Period, 18 months.
|
|
(5) |
These amounts assume that Mr. Tursi’s employment was terminated without cause or for good reason on the date of a change of control.
|
Plan Category
|
Number of securities
to be issued upon exercise of outstanding options, warrants and rights |
Weighted-
average exercise price of outstanding options, warrants and rights |
Number of securities
remaining available for future issuance under equity compensation plans (excluding shares reflected in the first column) |
Equity compensation plans approved by security holders
|
13,861
|
2.41
|
7,402
|
Equity compensation plans not approved by security holders
|
None
|
N/A
|
None
|
Name
|
Shares Beneficially
Owned
|
Percentage
of Outstanding
Shares
|
Blackrock Inc.
|
11,472,832(1)
|
7.0%
|
55 East 52nd Street
|
||
New York , NY 10055
|
||
Jacques Gonella, Ph.D.
|
9,444,039(2)
|
5.7%
|
Hauptstrasse 16
|
||
P.O. Box 333
Muttenz CH-4132
Switzerland
|
|
(1) |
This information is based solely on a review of an amendment to Schedule 13G filed with the SEC on February 5, 2020 by Blackrock Inc., which (i) beneficially owned 11,472,832 shares, (ii) had sole voting power over 11,210,523 shares,
(iii) had shared voting power of 0 shares, (iv) had sole dispositive power over 11,472,832 shares and (v) shared dispositive power over 0 shares.
|
|
(2) |
This information is based on a review ownership of shares of our Common Stock provided on behalf of Dr. Gonella on April 20, 2020 and also includes 568,191 shares of our Common Stock issuable upon the exercise of options exercisable
within 60 days of April 17, 2020.
|
Name
|
Shares Owned (1)
|
Right to Acquire (1) (2)
|
Total Shares
Beneficially Owned (1) (2) |
Percentage
of Outstanding Shares |
|
Robert F. Apple
|
1,427,335
|
2,795,164
|
4,222,499
|
2.5%
|
|
Thomas J. Garrity
|
170,213
|
534,920
|
705,133
|
*
|
|
Peter J. Graham
|
239,865
|
775,663
|
1,015,528
|
*
|
|
Peter Greenleaf
|
-
|
56,729
|
56,729
|
*
|
|
Anton G. Gueth
|
302,776
|
721,871
|
1,024,647
|
*
|
|
Leonard Jacob, M.D., Ph.D.
|
175,078
|
1,049,813
|
1,224,891
|
*
|
|
Fred M. Powell
|
339,719
|
546,546
|
886,265
|
*
|
|
Robert P. Roche, Jr.
|
88,172
|
534,920
|
623,092
|
*
|
|
Marvin Samson
|
27,778
|
284,920
|
312,698
|
*
|
|
Karen L. Smith, M.D., Ph.D.
|
-
|
55,062
|
55,062
|
*
|
|
James P. Tursi(3)
|
-
|
75,000
|
75,000
|
*
|
|
All directors, director nominees and executive officers as a group (11 persons)
|
2,770,936
|
7,430,608
|
10,201,544
|
5.9%
|
* |
Less than 1%.
|
(1) |
Beneficial ownership is determined in accordance with rules of the SEC, and includes generally voting power and/or investment power with respect to securities. In addition, shares of Common Stock subject to options currently exercisable
or exercisable within 60 days of April 17, 2020, are deemed outstanding for computing the percentage of the person holding such options but are not deemed outstanding for computing the percentage of any other person. Except as indicated by
footnote, the Company believes that the persons named in this table, based on information provided by such persons, have sole voting and investment power with respect to the shares of Common Stock indicated.
|
(2) |
Shares of our Common Stock issuable upon the exercise of options exercisable within 60 days of April 17, 2020.
|
(3) |
Dr. Tursi resigned effective April 17, 2020
|
1 Year Antares Pharma Chart |
1 Month Antares Pharma Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions